Pittsburgh, PA (December 21, 2004). -- Cellomics, Inc., the creator of and market leader in High Content Screening (HCS), announced today the launch of an upgrade package for their ArrayScan® HCS Reader instrument platform. 

The HCS Reader 2004 Upgrade is a high performance upgrade for existing ArrayScan HCS Reader customers which offers  a variety of hardware and software enhancements designed to support their HCS initiatives. The Upgrade delivers increased productivity, reliability, throughput, and ease-of-use. Many of these enhancements evolved out of the development of  the ArrayScan VTI HCS Reader, which was launched in late 2003.

The HCS Reader 2004 Upgrade consists of new software features and ease-of-use improvements as well as a new shutterless, high-performance camera, which provides increased sensitivity and reliability.  In addition, the Upgrade enables access to the V2 versions of Cellomics’ BioApplications (image analysis software modules) – the most extensive line of powerful, pre-packaged and easy-to-use algorithms available for analysis of cellular images.

“The upgrade has been developed directly from customer input and we’ve responded to those requests,” stated Judy P. Masucci, Ph.D., Director of Marketing and Sales Support at Cellomics, “We have a large number of customers who have been using Cellomics instruments for years and we want to make sure they get the best performance possible out of their investment in HCS.”

”Cellomics is the recognized leader in HCS for drug discovery.  We have taken that proven technology platform and upgraded it to ensure that all of our customers have affordable access to the best available HCS technology,” added Daniel J. Calvo, President and CEO of Cellomics.

About Cellomics

Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening (HCS).  The platform includes HCS instrumentation (both fixed end-point and kinetic systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays.  When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics’ proprietary platforms, including the ArrayScan and KineticScan® HCS Readers, along with BioApplications software and High Content Informatics (HCi™) suite, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies and academic centers globally. For more information about Cellomics, visit our website at www.cellomics.com.